Molecular structure of Troglitazone, CAS Number: 97322-87-7
Troglitazone (CAS 97322-87-7)
See product citations (9)
Application:
Troglitazone is a potent antiproliferative, apoptosis inducer, antioxidant, and antiinflammatory agent
CAS Number:
97322-87-7
Purity:
≥98%
Molecular Weight:
441.54
Molecular Formula:
C24H27NO5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Troglitazone may act to be a potent antiproliferative and apoptosis inducer. This compound has displayed a capacity to inhibit growth of HCC cells via G1 phase cell cycle arrest through hypophosphorylation of Rb (retinoblastoma) protein and an increase of the cyclin-dependent kinase inhibitors, p21 and p27 proteins. In addition, Troglitazone has been reported to have profound antioxidant and antiinflammatory effects, and found to suppress L-type and receptor operated Ca2+ channel and PKC (protein kinase C). Experiments have shown Troglitazone to bind and activate PPARgamma(peroxisome proliferator-activated receptor gamma). PPARgamma is mainly expressed in adipose tissue, one of the target tissues for insulin, but has subsequently been found to be expressed in vascular smooth muscle cells, endothelial cells, macrophages, and some cancer cells.
Troglitazone (CAS 97322-87-7) References
- Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. | Scheen, AJ. and Lefèbvre, PJ. 1999. Diabetes Care. 22: 1568-77. PMID: 10480527
- Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. | Tsubouchi, Y., et al. 2000. Biochem Biophys Res Commun. 270: 400-5. PMID: 10753637
- Troglitazone and related compounds: therapeutic potential beyond diabetes. | Fujiwara, T. and Horikoshi, H. 2000. Life Sci. 67: 2405-16. PMID: 11065164
- Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. | Okura, T., et al. 2000. Eur J Pharmacol. 407: 227-35. PMID: 11068018
- Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? | Aljada, A., et al. 2001. J Clin Endocrinol Metab. 86: 3250-6. PMID: 11443197
- The mechanisms of action of PPARs. | Berger, J. and Moller, DE. 2002. Annu Rev Med. 53: 409-35. PMID: 11818483
- Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. | Yoshizawa, K., et al. 2002. Cancer. 95: 2243-51. PMID: 12412180
- Troglitazone induced apoptosis via PPARγ activated POX-induced ROS formation in HT29 cells. | Wang, J., et al. 2011. Biomed Environ Sci. 24: 391-9. PMID: 22108328
- Troglitazone suppresses glutamine metabolism through a PPAR-independent mechanism. | Reynolds, MR. and Clem, BF. 2015. Biol Chem. 396: 937-47. PMID: 25872876
- Troglitazone Inhibits Bile Acid Amidation: A Possible Risk Factor for Liver Injury. | Ogimura, E., et al. 2017. Toxicol Sci. 158: 347-355. PMID: 28486596
- Encapsulation of troglitazone and AVE0991 by gelation microspheres promotes epithelial transformation of adipose-derived stem cells. | Tao, K., et al. 2020. Mol Cell Probes. 51: 101543. PMID: 32105703
- Troglitazone, a Selective Ligand for PPARγ, Induces Cell-cycle Arrest in Human Oral SCC Cells. | Saito, M., et al. 2020. Anticancer Res. 40: 1247-1254. PMID: 32132021
- Troglitazone inhibits hepatic oval cell proliferation by inducing cell cycle arrest through Hippo/YAP pathway regulation. | He, Y., et al. 2022. Dig Liver Dis. 54: 791-799. PMID: 34531129
- Troglitazone-Induced Autophagic Cytotoxicity in Lung Adenocarcinoma Cell Lines. | Tsujiya, Y., et al. 2022. Biol Pharm Bull. 45: 276-283. PMID: 35228393
Inhibitor of:
βPIX, AADACL1, AdipoR1, ATP-binding cassette (ABC) transporter, BSEP, C/EBP α, C/EBP β, C/EBP δ, CKR-2, EG226601, Galactose Mutarotase, Glucagon Receptor, Lipophilin B, LKLF, LRP2BP, LYCAT, mitoNEET, Musclin, O-Ac GD3, OATP-D, OATP-E, OATP-F, OATP-J, OATP16, Oatp2, OATP2A1, Oatp5, OPN, OTOP2, PAT2, Peroxin 11β, PNPLA7, Protein tyrosine phosphatase receptor (PTPR), PTP 1B, PTPκ, PTPψ, SLC10A6, Slco6c1, Slco6d1, SR-A, TGR5, TMPRSS11E2, TRB-3, TUG, Usherin, Vaspin, ZDHHC12, ZDHHC5, and Zfp13.Activator of:
17β-HSD6, 2410131K14Rik, 3β-HSD2, A-FABP, ABCF2, ABCG4, ACSVL5, Adipogenin, ADPGK, ALDH1A3, AMAC1L1, APC1, APG7, APM2, apoD, ATPIF1, C18orf34, C1orf144, C1orf63, C20orf195, carbonyl reductase 2, casein kinase Iδ, Caveolin-1, CBR4, CD163L1, CEACAM1, Ces1a, Ces1d, CES3, Ces3b, COX7b2, CPPED1, CTRP9, cylindromatosis 1, CYP2AB1, Cyp2c39, Cyp2c54, CYP2D40, CYP2J12, CYP2J8, CYP2R1, Cyp3a13, CYP3A4, CYP3A43, Cyp3a44, CYP3A5, CYP3A7, CYP3A7-CYP3AP1, Cyp4f40, cystatin F, DBC-2, Dbil5, Dcun1D1, DHRS11, DPY19L2, EG432995, EG546325, ELOVL1, ERR gamma, FACL6, Factor B, FAM57B, FBXW26, FMO4, FN3K, FNDC5, follistatin, GBE1, Glut14, Glut2, Glut4, GP-39, HACE1, HMG-I/HMG-Y, HNF-1α, HNF-4γ, hnRNP A1, ITM2B, Jun D, KLF14, L-FABP, LPAAT-δ, MBP, Mdr-3, megalin, mEH, MetAP-1, Mettl7a2-Higd1c, MondoA, MRP2, MRP3, NDC1, NEDD4, NOD2, NP220, OAT2, OATP-C, OATP8, OCT1, OXA1L, Pax-7, PDC-E2, PEPCK-C, PLAP, PPAR gamma, PPRC1, PTRF, pUb-R, PUMA, resistin, RHOBTB3, RORβ, Rtl1, SAP 14_SF3B14, SCARA5, Skint7, SLC22A9, SLC43A2, Slfn3, Snf1, SP-C, SRMS, Stat1, SULT1A3, SULT1A4, Syndecan-3, Tak1L, Tiam1, TIGD3, Tim17A, TMEM82, Tpbpa, Tpbpb, TRAC-1, TRIM16, UBE2E2, UGT2B7, USP17L2, utrophin, WDR40C, ZBTB42, and ZNF225.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Troglitazone, 5 mg | sc-200904 | 5 mg | $110.00 | |||
Troglitazone, 10 mg | sc-200904B | 10 mg | $204.00 | |||
Troglitazone, 25 mg | sc-200904A | 25 mg | $435.00 |